NASDAQ:CHRSCoherus Biosciences Stock Price, Forecast & News

Coherus Biosciences' stock was trading at $15.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CHRS shares have increased by 13.4% and is now trading at $18.00. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Coherus Biosciences.

Coherus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Coherus Biosciences.

Coherus Biosciences Inc (NASDAQ:CHRS) announced its earnings results on Thursday, May, 7th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.10. The biotechnology company had revenue of $116.18 million for the quarter, compared to analysts' expectations of $116.25 million. Coherus Biosciences had a net margin of 33.42% and a return on equity of 190.82%. View Coherus Biosciences' earnings history.

Coherus Biosciences issued an update on its first quarter 2020 Pre-Market earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $115-117.5 million, compared to the consensus revenue estimate of $118.85 million.

7 Wall Street analysts have issued 1-year price targets for Coherus Biosciences' shares. Their forecasts range from $26.00 to $43.00. On average, they expect Coherus Biosciences' share price to reach $32.57 in the next year. This suggests a possible upside of 81.0% from the stock's current price. View analysts' price targets for Coherus Biosciences.

News coverage about CHRS stock has been trending negative on Thursday, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Coherus Biosciences earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Coherus Biosciences.

Coherus Biosciences saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 18,290,000 shares, an increase of 18.6% from the June 15th total of 15,420,000 shares. Based on an average trading volume of 1,780,000 shares, the short-interest ratio is presently 10.3 days. Currently, 28.2% of the shares of the stock are sold short. View Coherus Biosciences' Current Options Chain.

Some companies that are related to Coherus Biosciences include Novavax (NVAX), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Halozyme Therapeutics (HALO), bluebird bio (BLUE), Fate Therapeutics (FATE), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Immunovant (IMVT), Alector (ALEC), Editas Medicine (EDIT) and Bill.com (RVMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Chembio Diagnostics (CEMI), Halozyme Therapeutics (HALO), Exelixis (EXEL), Intelsat (I), Bank of America (BAC), Heron Therapeutics (HRTX), Immunomedics (IMMU), Gilead Sciences (GILD), Iovance Biotherapeutics (IOVA) and Pfizer (PFE).

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

Coherus Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include DNB Asset Management AS (0.03%) and Envestnet Asset Management Inc. (0.02%). Company insiders that own Coherus Biosciences stock include Barbara K Finck, Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom and Vincent R Anicetti. View institutional ownership trends for Coherus Biosciences.

CHRS stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, and Vincent R Anicetti. View insider buying and selling activity for Coherus Biosciences.

CHRS stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS. View insider buying and selling activity for Coherus Biosciences.

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHRS stock can currently be purchased for approximately $18.00.

Coherus Biosciences has a market capitalization of $1.28 billion and generates $356.07 million in revenue each year. The biotechnology company earns $89.83 million in net income (profit) each year or $1.23 on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe.

The official website for Coherus Biosciences is www.coherus.com.

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]